In Brief: Recombinant DNA Advisory Committee
Recombinant DNA Advisory Committee: Senate Appropriations Committee asks the National Institutes of Health to submit for the record justification for the elimination of the RAC. NIH announced in the July 8 Federal Register that the RAC would be abolished and replaced by gene therapy policy conferences and a new advisory committee for the NIH Office of Recombinant DNA Activities ("The Pink Sheet" July 8, T&G-3)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth